What’s new

• Ikoma plans to raise up to ₹50 cr via a rights issue to fund the acquisition of 51% of ICM Insurance Brokers.
• The acquisition price is about ₹30 cr. ICM's turnover jumped to ₹31.42 cr in FY26 from ₹10.63 cr prior.
• The move pivots the nano-cap away from its core business, which saw revenue collapse to ₹1.66 cr last year.

Why it matters

This is a lifeboat. Ikoma's own business is nearly gone, and it is using a massive dilutive raise to buy into a different company altogether. The rights issue is huge relative to its tiny market cap, meaning existing shareholders will face severe dilution unless they subscribe. The target's revenue growth is real, but the bet is on the quality of that business, not on Ikoma itself.

What we’re watching

• Whether ICM's business is what Ikoma's filing claims—₹31 cr turnover from a nano-cap's perspective is a different company.
• Regulatory and shareholder approval for a rights issue this large relative to market cap.
• What happens to Ikoma's remaining ₹1.66 cr business after the pivot.

The full read

Ikoma Technologies, a nano-cap with barely any revenue left, is going all-in on insurance broking. The company plans to raise ₹50 cr through a rights issue to buy a 51% stake in ICM Insurance Brokers for about ₹30 cr. The raise is equivalent to 38% of Ikoma's ₹133 cr market cap. For a company whose own revenue cratered to ₹1.66 cr last year from ₹19.83 cr, this is an existential pivot, not a strategic one. ICM's numbers are far bigger: its turnover jumped to ₹31.42 cr in the year ended March 2026 from ₹10.63 cr prior. The question isn't whether Ikoma is buying a better business. It's whether a ₹1.66 cr company can successfully digest one that's nearly 20 times its size.

Primary source: BSE · NSE